

EMEA/MB/663707/2008Adopted Version: 3.0, CURRENT, Adopted

Sixty second meeting of the Management Board

4 March 2009 (Room 4A) 3pm – 8pm

Agenda

1.	Introduction	Chairman	3:00pm – 3:15pm
2.	Future challenges and directions	Thomas Lönngren	3:15pm – 4.00pm
3.	Risk-based prioritisation of resources	Chris Verdonck, Sophie Janssens and Michel De Ridder Deloitte	4.00pm – 5:00pm
4.	Tea and coffee break (4 th floor open area)		5:00pm – 5:15pn
5.	Challenges linked to the globalisation of clinical trials	Charles S. Mgone, European & Developing Countries Clinical Trials Partnership	5.15pm - 6.15pm
6.	Dinner (3rd floor function room)		6.30pm-8.00pm

5 March 2009 (Room 4A) 9am to 4pm <u>Draft Agenda</u>

1.	Draft agenda	For adoption, EMEA/MB/663707/2008*		
2.	Start of the term of office of the Management Board members nominated by the Council	For adoption, EMEA/MB/87076/2009*		
3.	Declaration of conflicts of interest	Oral report		
4.	Elections of vice-chair	Oral report		
5.	Minutes from the 61 st meeting, held on 11 December 2008, adopted via written procedure on 28 January 2009	For information, EMEA/MB/671250/2008*		
6.	EMEA highlights from the Executive Director 6.1. Outcome of the EMEA transparency policy workshop	Oral report Oral report		
7.	EMEA annual report 2008 7.1. Preparation for written procedure for adoption of the EMEA annual report 2008	For discussion, EMEA/MB/684002/2008		
8.	Draft EMEA work programme and budget for 2010:	For adoption, EMEA/MB/632200/2008		
	8.1. Preliminary draft work programme8.2. Preliminary draft budget	For adoption, EMEA/MB/502942/2008 For information, EMEA/MB/94586/2009		
	Information technology8.3. Staff policy plan	For adoption, EMEA/MB/579221/2008		
9.	9. Incentives for MUMS/limited markets products 9.1. Analysis and risk assessment of the financial and budgetary impact of the fee incentives proposed under MUMS/Limited market 9.2. Procedural Advice for Classification and Incentives for Veterinary Medicinal Products Indicated For Minor Use Minor Species (MUMS)Limited Markets For information, EMEA/MB/67287/2009 For endorsement, EMEA/MB/58755/2009			
10.	Draft mandate for Management Board task force on scient qualifications of committee members	ific For adoption, EMEA/MB/673201/2008*		
11.	Rules of procedure for: 11.1. the Committee for Medicinal Products for Human U 11.2. the Committee for Advanced Therapies 11.3. Draft procedural advice on evaluation of Advanced Therapy Medicinal Products	For discussion, EMEA/CHMP/89672/2009 For discussion, EMEA/103390/2009 EMEA/118727/2009		
12.	Revised organisational structure of the EMEA	Oral report		
	Updated EMEA Quality policy For endorsement, EMEA/MB/355781/2007Rev.			
	14. Preparation for Written procedure on changes to The Rules for Implementation of Regulation (EC) No 297/95, as amended, on Fees Payable to the EMEA and other measures, in particular: 14.1. Fees relating to Veterinary Medicinal Products Indicated For Minor Use Minor Species (MUMS)Limited Markets 14.2. Fees relating to Medicinal Products to be Used in a Human Pandemic situation			
15.	Proposal for involvement and participation of patients'/correpresentatives in the meetings of the CHMP PhVWP	rsumers' For endorsement, EMEA/261645/2008*		
16.	Governance of the EU agencies	For discussion		
17.	Report from the European Commission	Oral report		

18. Report from the Heads of Medicines Agencies

Oral report

- 19. Points for information:
 - 19.1. Survey 2008 on the performance of EMEA scientific procedures for medicinal products for human use
 - 19.2. Update report on EMEA implementation of EU telematics strategy
 - 19.3. Report on EudraVigilance implementation:
 - Veterinary
 - Human
 - 19.4. Outcome of written procedures on consultation on changes in the membership of the CHMP and CVMP committees
 - 19.5. Summary of transfers of appropriations in the budget 2008 and 2009

For information, EMEA/MB/30754/2009*

For information, EMEA/MB/20870/2009*

For information,

EMEA/86607/2009* EMEA/MB/45112/2009*

For information, EMEA/MB/81661/2009

For information, EMEA/MB/649766/2008*

Documents marked * are intended for publication on Management Board external web site.